Skip to main content
. 2020 Dec 7;6(2):414–428. doi: 10.1016/j.ekir.2020.11.026

Figure 5.

Figure 5

Baseline risk of progression in the Glomerular Research And Clinical Experiments–IgA Nephropathy in Indians (GRACE-IgANI) cohort using 2 different risk prediction scores. (a) We calculated the 5-year risk of a 50% decline in eGFR or ESKD using the International IgA Nephropathy Network (IIGANN) risk prediction tool (Barbour et al.) and the 5-year risk of ESKD using the renal risk equation developed by Tanaka et al. for the 185 IgAN patients with complete MEST-C scores in the GRACE-IgANI cohort. Each patient is represented in a separate column and ordered according to increasing 5 year risk of ESKD using the renal risk equation developed by Tanaka et al. (b) There was a clear correlation between each patients 5-year risk of a 50% decline in eGFR or ESKD using the International IgA Nephropathy Network (IIGANN) risk prediction tool (Barbour et al.) and the 5-year risk of ESKD using the renal risk equation developed by Tanaka et al. for the 185 IgAN patients with complete MEST-C scores in the GRACE-IgANI cohort. As would be expected a number of patients with no risk of ESKD at 5 years using the Tanaka et al. prediction tool had appreciable risk of progression using the IIGANN tool which likely represents those at risk of a 50% decline in eGFR rather than ESKD within 5 years. (c) We also calculated the corresponding 2 year risk of a 50% decline in eGFR or ESKD using the International IgA Nephropathy Network (IIGANN) risk prediction tool (Barbour et al.) in the 185 IgAN patients with complete MEST-C scores in the GRACE-IgANI cohort. Short term risk of progression in this incident cohort was high.